Device Grouping Rules for Myanmar Registration

1. Key takeaways

The Technical Guidance for Online Submission of Medical Devices in Myanmar contains a dedicated Grouping chapter, which sets out whether multiple models can be merged into a single application. This rule stands alongside the classification rules (Section 2) and the labelling rules (Section 3) as one of the three major technical rules of the guidance.

GRZAN note: the direct effect of the grouping rules on the company side is on the number of application units and the fee structure. A successful grouping can significantly reduce the per-model cost and the review burden; a failed grouping means separate submissions for multiple application units, each carrying its own documents, fees and review timeline. Because the specific criteria in Section 4 of the guidance must be read against the current text, companies preparing multi-model applications should first confirm the grouping position with the Myanmar FDA before drafting documents in batch. The coordinates of the rules are worth remembering: grouping sits in Section 4 of the guidance, classification in Section 2, and labelling in Section 3, making 3 technical rules in total. Reading these three sections together at the start of any multi-model project is the cheapest possible form of insurance against structural rework.

2. Legal basis

3. Expert insights

Insight 1: grouping and classification are two different matters and must be determined separately. Classification determines the risk class; grouping determines the number of application units. Products in the same class may be required to be split, or allowed to be merged, depending on the grouping rules, so a favourable classification conclusion says nothing about the application structure. Companies that treat the two determinations as a single exercise tend to discover the difference only when the FDA returns the application with a request to split it.

Insight 2: the grouping determination should be made before document preparation starts. The grouping conclusion decides how many document sets are needed and how many fees are payable. If documents are drafted first and the grouping confirmed afterwards, the drafting may have to be redone because of split or merge requirements, wasting weeks of work. Sequencing the enquiry first also gives the FDA’s answer time to arrive while the document team is still working on content that is unaffected by the grouping outcome.

Insight 3: the letter of authorisation must cover all models within the group. The authorities require the letter of authorisation to define the device scope, including product names, models and the manufacturer address. Models not listed in the letter of authorisation cannot be added later through a simple variation and must be handled separately. This is why the grouping decision and the authorisation scope should be agreed in the same meeting, not in successive weeks.

Insight 4: the grouping rules are governed by the current text of the guidance. The specific criteria (for example, grouping by intended use, by technical characteristics or by sterilisation method) must be read in Section 4 of the guidance; this article does not substitute its own interpretation. Where the guidance text leaves room for interpretation, the written FDA confirmation described above is the only reliable anchor.

Insight 5: the grouping strategy should be coordinated with commercial model management. If the model naming system does not match the grouping logic, the number of application units inflates artificially and drives up cost. Aligning the naming scheme with plausible grouping criteria at the product design stage is a low-cost way to protect registration efficiency, and it also simplifies maintenance of the registration portfolio over its lifetime.

4. Practical recommendations

• Confirm the grouping position before drafting documents. Make the enquiry to the FDA through the local authorised representative and record the conclusion.
• Let the letter of authorisation cover every model intended for grouping. Avoid supplementary applications caused by omissions.
• Prepare document sets according to the grouping conclusion. Not one set per individual model.
• Adapt the model naming system to the grouping rules. consider application efficiency as early as the product design stage, because renaming models after submission is far more disruptive than naming them correctly the first time.
• Record the grouping conclusion in the registration ledger. This makes it traceable at renewal and at the time of any variation.

5. Verification checklist

• □ The current text of the grouping rules in Section 4 of the guidance has been reviewed
• □ It has been confirmed that the models intended for grouping meet the grouping conditions
• □ Written FDA confirmation of the grouping position has been obtained
• □ The letter of authorisation covers all models to be submitted
• □ Document sets have been prepared according to the grouping conclusion
• □ The grouping conclusion has been entered in the registration ledger
• □ The model naming system has been aligned with the grouping rules

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com